These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25901962)

  • 1. Correction: Recombinant NAD-dependent SIR-2 protein of Leishmania donovani: immunobiochemical characterization as a potential vaccine against visceral leishmaniasis.
    Baharia RK; Tandon R; Sharma T; Suthar MK; Das S; Siddiqi MI; Saxena JK; Sundar S; Dube A
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003742. PubMed ID: 25901962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.
    Aguilar-Be I; da Silva Zardo R; Paraguai de Souza E; Borja-Cabrera GP; Rosado-Vallado M; Mut-Martin M; García-Miss Mdel R; Palatnik de Sousa CB; Dumonteil E
    Infect Immun; 2005 Feb; 73(2):812-9. PubMed ID: 15664920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leishmania donovani: impairment of the cellular immune response against recombinant ornithine decarboxylase protein as a possible evasion strategy of Leishmania in visceral leishmaniasis.
    Yadav A; Amit A; Chaudhary R; Chandel AS; Mahantesh V; Suman SS; Singh SK; Dikhit MR; Ali V; Rabidas V; Pandey K; Kumar A; Das P; Bimal S
    Int J Parasitol; 2015 Jan; 45(1):33-42. PubMed ID: 25449949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
    Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC
    Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leishmanization revisited: immunization with a naturally attenuated cutaneous Leishmania donovani isolate from Sri Lanka protects against visceral leishmaniasis.
    McCall LI; Zhang WW; Ranasinghe S; Matlashewski G
    Vaccine; 2013 Feb; 31(10):1420-5. PubMed ID: 23219435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction: High accuracy of an ELISA test based in a flagella antigen of Leishmania in serodiagnosis of canine visceral leishmaniasis with potential to improve the control measures in Brazil-A Phase II study.
    Borja LS; Coelho LB; de Jesus MS; de Queiroz ATL; Celedon PAF; Zanchin NIT; Silva ED; Ferreira AGP; Krieger MA; Veras PST; Fraga DBM
    PLoS Negl Trop Dis; 2020 May; 14(5):e0008346. PubMed ID: 32433699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis.
    Selvapandiyan A; Dey R; Gannavaram S; Solanki S; Salotra P; Nakhasi HL
    Vaccine; 2014 Jun; 32(31):3895-901. PubMed ID: 24837513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis.
    Samant M; Gupta R; Kumari S; Misra P; Khare P; Kushawaha PK; Sahasrabuddhe AA; Dube A
    J Immunol; 2009 Jul; 183(1):470-9. PubMed ID: 19542458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmania genome analysis and high-throughput immunological screening identifies tuzin as a novel vaccine candidate against visceral leishmaniasis.
    Lakshmi BS; Wang R; Madhubala R
    Vaccine; 2014 Jun; 32(30):3816-22. PubMed ID: 24814525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction: Age trends in asymptomatic and symptomatic Leishmania donovani infection in the Indian subcontinent: A review and analysis of data from diagnostic and epidemiological studies.
    PLOS Neglected Tropical Diseases Staff
    PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007150. PubMed ID: 30807580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Leishmania donovani disulfide isomerase as a potential target of cellular immunity against visceral leishmaniasis.
    Amit A; Chaudhary R; Yadav A; Suman SS; Narayan S; Das VN; Pandey K; Singh SK; Singh BK; Ali V; Das P; Bimal S
    Cell Immunol; 2014; 289(1-2):76-85. PubMed ID: 24732062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptation of Leishmania donovani to cutaneous and visceral environments: in vivo selection and proteomic analysis.
    McCall LI; Zhang WW; Dejgaard K; Atayde VD; Mazur A; Ranasinghe S; Liu J; Olivier M; Nilsson T; Matlashewski G
    J Proteome Res; 2015 Feb; 14(2):1033-59. PubMed ID: 25536015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Leishmania donovani ribosomal P1 gene as DNA vaccine in experimental visceral leishmaniasis.
    Masih S; Arora SK; Vasishta RK
    Exp Parasitol; 2011 Sep; 129(1):55-64. PubMed ID: 21640106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge.
    Kushawaha PK; Gupta R; Sundar S; Sahasrabuddhe AA; Dube A
    J Immunol; 2011 Dec; 187(12):6417-27. PubMed ID: 22079980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani.
    Gamboa-León R; Paraguai de Souza E; Borja-Cabrera GP; Santos FN; Myashiro LM; Pinheiro RO; Dumonteil E; Palatnik-de-Sousa CB
    Vaccine; 2006 May; 24(22):4863-73. PubMed ID: 16635538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
    Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
    Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of Leishmania donovani.
    Sharma A; Madhubala R
    J Immunol; 2009 Dec; 183(12):7719-31. PubMed ID: 19933862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intradermal Immunization of Leishmania donovani Centrin Knock-Out Parasites in Combination with Salivary Protein LJM19 from Sand Fly Vector Induces a Durable Protective Immune Response in Hamsters.
    Fiuza JA; Dey R; Davenport D; Abdeladhim M; Meneses C; Oliveira F; Kamhawi S; Valenzuela JG; Gannavaram S; Nakhasi HL
    PLoS Negl Trop Dis; 2016 Jan; 10(1):e0004322. PubMed ID: 26752686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetically Engineered Ascorbic acid-deficient Live Mutants of Leishmania donovani induce long lasting Protective Immunity against Visceral Leishmaniasis.
    Anand S; Madhubala R
    Sci Rep; 2015 Jun; 5():10706. PubMed ID: 26035062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.